drugset / Trial / NCT04716998
Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19
Non-randomizedSequentialOpen-labelTreatment
Summary
An open label clinical study to evaluate the safety and the efficacy of MesenCure, an allogeneic cell therapy product, for the treatment of the pulmonary manifestations in COVID19 patients
Timeline
- Start
- 2021-01-14
- Primary completion
- 2022-01-31
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MesenCure | Cell therapy | — | Intravenous |